HIV vaccine - Advanced BioScience Laboratories/NIAID

Drug Profile

HIV vaccine - Advanced BioScience Laboratories/NIAID

Latest Information Update: 03 Oct 2012

Price : $50

At a glance

  • Originator Advanced BioScience Laboratories; National Institutes of Health (USA)
  • Developer Advanced BioScience Laboratories
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 03 Oct 2012 Advanced BioScience awards development and manufacturing contract to Avid Bioservices to support cGMP production of HIV gp145 envelope protein
  • 11 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections pharmacodynamics section
  • 09 Aug 2004 Data presented at the 15th International AIDS Conference (IAC-2004) have been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top